Nearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual abnormalities in 5% of women. AstraZeneca’s vaccine technology controversy and Covishield’s development by the Serum Institute of India are notable. The study reported viral upper respiratory tract infections in adolescents and adults.